Technology | ECG | October 08, 2015

CardioSecur 22-Lead Mobile ECG Enables 360-Degree View of the Heart

Device with mobile application allows 10,000 minutes of ECG recording per 1GB via smartphone or tablet

CardioSecur mobile ECG, 22-lead, 360 degree view of the heart, CardioSecur Pro

Image courtesy of CardioSecur

October 8, 2015 — Personal MedSystems introduced the first and only 22-lead mobile electrocardiogram (ECG) system, CardioSecur, at the European Society of Cardiology Congress 2015, Aug. 29-Sept. 2 in London. The next generation of ECG solutions can be run with a smartphone or tablet PC, four electrodes and the CardioSecur App enabling the diagnosis and localization of cardiac ischemia, rhythm disorders and posterior wall infarctions. Clinical-grade quality readings allow a 360-degree view of the heart and therefore new diagnostic possibilities. CardioSecur's technology has been validated in several clinical studies and is available in two versions: CardioSecur Pro for professional use and CardioSecur Active for home use by patients.

The conventional 12-lead ECG has surely proven its worth in the diagnosis of cardiac disease. Nevertheless the display possibilities of a 12-lead ECG are limited to only 65 degrees in the transverse plane. This might be one of the reasons up to half of people who suffer from angina or silent ischemia, have normal ECG readings. In Europe alone, coronary artery disease still accounts for 4 million deaths every year. Symptoms for myocardial infarction are often indistinct while about one out of three heart attacks occurs symptom-free, which makes precise diagnosis even more difficult. Next to modern therapy options the need for enhanced diagnosis tools supporting physicians is crucial.

Quality and accuracy of CardioSecur has been validated in a clinical study against standard-of-care 10-electrode, 12-lead ECG systems and shows 99.5 percent accuracy. Using only four electrodes mitigates artifacts to a bare minimum, ensuring maximum signal quality and stable lead depiction. As the four electrodes are placed on very marked positions of the thorax, lead misplacement, often consequential to highly divers anatomies, is eradicated.

The professional 22-lead version CardioSecur Pro enables use in house calls, bed-ridden or reduced mobility patients as well as emergency situations. The lightweight 50g cable is accompanied by the Pro app which allows 10,000 minutes of ECG recording per 1GB via smartphone or tablet PC. The full ECG report can be sent directly to electronic patient records or colleagues and can be air printed. An automatic interpretation function is also available.

For more information:

Related Content

Sedentary Lifestyle Cancels Out Heart Benefits of Normal Weight
News | Cardiac Diagnostics | January 09, 2019
January 9, 2019 — Researchers at the University of Florida have found that low levels of physical activity can put he
Livongo Launches Applied Health Signals Product Category
News | Cardiac Diagnostics | November 30, 2018
Healthcare technology company Livongo recently announced the launch of its Applied Health Signals product category,...
HHS Releases Second Edition of Physical Activity Guidelines for Americans. #AHA2018 #AHA18
News | Cardiac Diagnostics | November 14, 2018
The U.S. Department of Health and Human Services (HHS) released the second edition of the Physical Activity Guidelines...
ACC and AHA Release Updated Cholesterol Guidelines for 2018. #AHA18 #AHA2018
Feature | Cardiac Diagnostics | November 13, 2018
November 13, 2018 — New cholesterol guidelines from the American Heart Association (AHA) and the American College of
AMI READMITS Score Predicts Heart Attack Patients at High Readmission Risk
News | Cardiac Diagnostics | October 09, 2018
Tracking just seven factors of heart attack patients when they are first admitted to the hospital can help flag those...
Siemens Healthineers Showcases New In Vivo and In Vitro Cardiovascular Solutions at TCT 2018
News | Cardiac Diagnostics | September 21, 2018
At the 2018 Transcatheter Cardiovascular Therapeutics (TCT) conference, Sept. 21-25 in San Diego, Siemens Healthineers...
Weight Loss Drug Does Not Increase Cardiovascular Events
News | Cardiac Diagnostics | August 31, 2018
A weight loss drug does not increase cardiovascular events, according to late breaking results from the CAMELLIA-TIMI...
Acarix Presents CADScor System at ESC 2018
News | Cardiac Diagnostics | August 27, 2018
Acarix AB’s ultra-sensitive acoustic CADScor System for coronary artery disease risk assessment will be on display at...
NIH Ending Funding for Moderate Alcohol and Cardiovascular Health Trial
News | Cardiac Diagnostics | August 24, 2018
The National Institutes of Health announced in June it plans to end funding to the Moderate Alcohol and Cardiovascular...
Study Shows Multiple Benefits of Patient-to-Patient Connectivity in Familial Chylomicronemia Syndrome
News | Cardiac Diagnostics | August 07, 2018
Akcea Therapeutics Inc., an affiliate of Ionis Pharmaceuticals Inc., announced the publication of results from the...
Overlay Init